Applications Face Rejection As China FDA Starts ‘Intensive Review’
This article was originally published in The Pink Sheet Daily
In a rare move, the China FDA has rejected 11 new drug applications from eight companies that were in its review queue, signaling more action to come as the agency ups punishments for clinical data forgery and prepares another intensive review campaign, its third in a decade.
You may also be interested in...
Touting its coronavirus vaccines as a "global public good", China is quietly preparing for the first general approvals and launches, possibly within weeks, developers say. But who will be first in line to receive them? And at what cost? Distribution and pricing are just some of the unanswered questions.
China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.
China’s National Medical Products Administration has released key regulations and proposals designed to encourage first generics through a 12-month market exclusivity proposal.